Business Wire

EXCLUSIVE-NETWORKS

22.2.2021 10:02:08 CET | Business Wire | Press release

Share
Exclusive Networks Grows X-OD Reach to 9 European Markets to Introduce Complete Fortinet Security Fabric Portfolio on a Subscription Basis

Exclusive Networks today unveiled the latest evolution of its X-OD platform with expansion into Germany, Spain, Belgium, Finland, Austria and Ireland. This coincides with the introduction of Fortinet to the X-OD portfolio offering, with the end-to-end availability of all Fortinet solutions through the Fortinet Security Fabric on a subscription basis – a unique channel proposition in global distribution.

X-OD is now available to partners in 9 European markets (France, UK and the Netherlands already launched) with aggressive plans to extend into all global regions later this year. Exclusive Networks is growing its subscription revenues 5x faster than traditional capex-based sales, with X-OD a significant driver in the acceleration of market evolution.

“Wherever we go with X-OD, it is growing fast – now in the Nordics, Iberia and DACH, and across Benelux, UK&I and France,” said Jesper Trolle, CEO of Exclusive Networks. “The global pandemic has undoubtedly accelerated digital transformation more generally, making this proposition even more relevant to business needs. Digital customer experience, big data insights and opex-based consumption are here to stay. And our roadmap is on track to extend the capabilities of X-OD beyond Europe and into every Exclusive operating territory.”

The enhanced opportunities made possible by X-OD are particularly relevant when it comes to key technologies such as SD-WAN and market segments such as MSSP. Customer organisations face the challenge of shifting from predominantly opex-based MPLS investments into a large-scale, capex-based network evolution to SD-WAN infrastructure. These issues are negated and opportunities unlocked by X-OD-enabled consumption models.

In the case of MSSP partners who ordinarily face investing upfront in the infrastructure capabilities to drive their own managed security services, X-OD enables them to buy technology in the same way they sell it. The sheer breadth, diversity of complementary nature of Fortinet’s portfolio also benefits from X-OD’s ability to ‘subscriptionise’ products and services into discreet packages, and even allow partners to bundle these with their own service wraps that are elegantly presented to customers as a single, easy-to-consume offering. Partners benefit yet further from X-OD’s fully digital customer experience and access to rich data insights that fuel upsell/cross-sell initiatives and targeted sales campaigns.

“Fortinet’s partnership with Exclusive Networks is geared to create exceptional value and opportunity for our partners and customers,” said Patrice Perche, Chief Revenue Officer & EVP Support at Fortinet. “With X-OD, Exclusive has engineered another genuinely innovative contribution to channel dynamics that aligns with how we see the world and how we want our partners to be enabled and supported. This represents significant benefits to all levels of our partner community, and ultimately provides our customers with new ways of consuming our market-defining products and services.”

“We see fantastic opportunities for the vendors who have committed to X-OD, and are very excited to introduce Fortinet and its extensive portfolio of solutions in these early stages of worldwide rollout,” added Jesper Trolle. “We are aligned with theirs and our other vendor partners’ visions for innovation, recurring revenue and market flexibility. Together we are empowering channel partners to make a fast, safe and simple transition to subscription-based consumption both for their customers and their own business models, allowing them to sell ‘everything as a service’.”

About X-OD

X-OD is an on-demand platform that brings together and enhances all of Exclusive Networks’ products and services in one, user-friendly place. The platform is the centre of a new digitalised technology distribution ecosystem that is connecting the full value chain, bringing vendors and resellers closer to their customers.

X-OD is pivotal in enabling the shift to the subscription business model. The platform is transforming capex to opex payments, enabling technology to be bought in the same way it is sold and consumed. It is this flexibility combined with on-demand functionality, speed and simplicity that makes X-OD so relevant in a ‘customer-first’ world. www.x-od.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye